Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

@article{McQueen2018CostEffectivenessOB,
  title={Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations},
  author={R. McQueen and Danielle N. Sheehan and M. Whittington and J. F. V. Boven and J. Campbell},
  journal={PharmacoEconomics},
  year={2018},
  volume={36},
  pages={957-971}
}
  • R. McQueen, Danielle N. Sheehan, +2 authors J. Campbell
  • Published 2018
  • Medicine
  • PharmacoEconomics
  • BackgroundRecently developed asthma biological therapies have been shown to provide relief for severe asthma patients not controlled by inhaled treatment. Given the relatively high costs of biological therapies, cost-effectiveness analyses (CEAs) may be required as a prerequisite for coverage and reimbursement.ObjectiveWe aimed to systematically review published literature on the economic impact of biological asthma therapies and to identify key drivers that impact cost-effectiveness in order… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 67 REFERENCES
    Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    25
    Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.
    91
    Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain
    19
    Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands
    40
    Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
    19
    Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    33
    Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.
    6